Used in the treatment of chronic myeloid leukemia (CML), particularly in patients who are resistant to standard therapies. It works by inhibiting protein synthesis in cancer cells, leading to cell cycle arrest and apoptosis. Its application has been explored in clinical settings for acute myeloid leukemia (AML) and other myeloproliferative disorders. Due to its mechanism of action, it shows potential in targeting leukemic stem cells, which are often responsible for relapse. Clinical use is limited by toxicity and availability, but it remains an option in specialized treatment protocols.